HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.

Abstract
Systemic infections caused by extraintestinal pathogenic Escherichia coli (ExPEC) have emerged as the most common community-onset bacterial infections and are major causes of nosocomial infections worldwide. The management of ExPEC infections has been complicated by the heterogeneity of ExPEC strains and the emergence of antibiotic resistance, thus their prevention through vaccination would be beneficial. The protective efficacy of four common ExPEC antigen candidates composed of common pilus antigens EcpA and EcpD and iron uptake proteins IutA and IroN, were tested by both active and passive immunization in lethal and non-lethal murine models of sepsis. Additionally, antibody raised to a synthetic form of a conserved surface polysaccharide, β-(1-6)-linked poly-N-acetylglucosamine (dPNAG) containing 9 monomers of (non-acetylated) glucosamine (9GlcNH2) conjugated to tetanus toxoid TT (9GlcNH2-TT) was tested in passive immunization protocols. Active immunization of mice with recombinant antigens EcpA, EcpD, IutA, or IroN elicited high levels of total IgG antibody of IgG1/IgG2a isotypes, and were determined to be highly protective against E. coli infection in lethal and non-lethal sepsis challenges. Moreover, passive immunization against these four antigens resulted in significant reductions of bacteria in internal organs and blood of the mice, especially when the challenge strain was grown in iron-restricted media. Inclusion of antibodies to PNAG increased the efficacy of the passive immunization under conditions where the challenge bacteria were grown in LB medium but not in iron-restricted media. The information and data presented are the first step toward the development of a broadly protective vaccine against sepsis-causing E. coli strains.
AuthorsMelha Mellata, Natalie M Mitchell, Florian Schödel, Roy Curtiss Rd, Gerald B Pier
JournalVaccine (Vaccine) Vol. 34 Issue 5 Pg. 656-662 (Jan 27 2016) ISSN: 1873-2518 [Electronic] Netherlands
PMID26707217 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2015 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • EcpA protein, E coli
  • Escherichia coli Proteins
  • Escherichia coli Vaccines
  • Immunoglobulin G
  • IroN protein, E coli
  • Molecular Chaperones
  • Receptors, Cell Surface
  • Vaccines, Conjugate
  • beta-Glucans
  • ecpD protein, E coli
  • poly-N-acetyl-1-6-glucosamine
  • Fimbriae Proteins
Topics
  • Animals
  • Antibodies, Bacterial (blood)
  • Antigens, Bacterial (immunology)
  • Escherichia coli Infections (prevention & control)
  • Escherichia coli Proteins (immunology)
  • Escherichia coli Vaccines (immunology)
  • Female
  • Fimbriae Proteins (immunology)
  • Immunization, Passive
  • Immunoglobulin G (blood)
  • Mice
  • Molecular Chaperones (immunology)
  • Rabbits
  • Receptors, Cell Surface (immunology)
  • Sepsis (prevention & control)
  • Vaccines, Conjugate (immunology)
  • beta-Glucans (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: